CN109963567A - 胆汁酸衍生物的结晶形式 - Google Patents

胆汁酸衍生物的结晶形式 Download PDF

Info

Publication number
CN109963567A
CN109963567A CN201780071347.7A CN201780071347A CN109963567A CN 109963567 A CN109963567 A CN 109963567A CN 201780071347 A CN201780071347 A CN 201780071347A CN 109963567 A CN109963567 A CN 109963567A
Authority
CN
China
Prior art keywords
compound
crystal form
crystalline form
xrpd
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071347.7A
Other languages
English (en)
Chinese (zh)
Inventor
雷切尔·皮内达斯特拉齐克
凯文·沙布
A·埃伯林
罗莎·玛丽亚埃斯皮诺萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CN109963567A publication Critical patent/CN109963567A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201780071347.7A 2016-09-30 2017-09-29 胆汁酸衍生物的结晶形式 Pending CN109963567A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402813P 2016-09-30 2016-09-30
US62/402,813 2016-09-30
PCT/US2017/054227 WO2018064441A1 (en) 2016-09-30 2017-09-29 Crystalline forms of a bile acid derivative

Publications (1)

Publication Number Publication Date
CN109963567A true CN109963567A (zh) 2019-07-02

Family

ID=61760943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071347.7A Pending CN109963567A (zh) 2016-09-30 2017-09-29 胆汁酸衍生物的结晶形式

Country Status (11)

Country Link
US (1) US20200024299A1 (https=)
EP (1) EP3518937A4 (https=)
JP (1) JP2019529481A (https=)
KR (1) KR20190057108A (https=)
CN (1) CN109963567A (https=)
AU (1) AU2017336803A1 (https=)
BR (1) BR112019006242A2 (https=)
CA (1) CA3038534A1 (https=)
IL (1) IL265621A (https=)
MX (1) MX2019003684A (https=)
WO (1) WO2018064441A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522703A (zh) * 2006-06-27 2009-09-02 英特塞普特医药品公司 胆酸派生物作为fxr配基预防或治疗fxr-介导的疾病或状况
CN105102425A (zh) * 2012-10-26 2015-11-25 英特塞普特医药品公司 制备胆汁酸衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528752A (zh) * 2006-10-16 2009-09-09 辉瑞产品公司 治疗性吡唑基噻吩并吡啶
JP5441705B2 (ja) * 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
SI3336097T1 (sl) * 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
HUP1300504A2 (en) * 2013-08-27 2015-03-30 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sorafenib salts
US10604544B2 (en) * 2015-08-07 2020-03-31 Intercept Pharmaceuticals, Inc. Methods for preparation of bile acids and derivatives thereof
AU2016325619A1 (en) * 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522703A (zh) * 2006-06-27 2009-09-02 英特塞普特医药品公司 胆酸派生物作为fxr配基预防或治疗fxr-介导的疾病或状况
CN105102425A (zh) * 2012-10-26 2015-11-25 英特塞普特医药品公司 制备胆汁酸衍生物的方法

Also Published As

Publication number Publication date
WO2018064441A1 (en) 2018-04-05
KR20190057108A (ko) 2019-05-27
AU2017336803A1 (en) 2019-04-18
CA3038534A1 (en) 2018-04-05
EP3518937A1 (en) 2019-08-07
BR112019006242A2 (pt) 2019-06-18
JP2019529481A (ja) 2019-10-17
IL265621A (en) 2019-05-30
MX2019003684A (es) 2019-08-05
EP3518937A4 (en) 2020-04-29
US20200024299A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
CN114605406B (zh) Amg510化合物的晶型及其制备方法和用途
EP3336097B1 (en) Preparation of the non-crystalline form of obeticholic acid
CN109963567A (zh) 胆汁酸衍生物的结晶形式
JP7371006B2 (ja) Ｐ３００及び／又はｃｂｐの調節因子を調製するための方法
US20210139528A1 (en) Crystalline forms of obeticholic acid
CN103664922A (zh) 新晶型阿齐沙坦及其制备方法
JP7638031B2 (ja) ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法
HK40003943A (zh) 胆汁酸衍生物的结晶形式
CN113166168A (zh) 噻吩并吡啶酮衍生物的一水合钾盐及其制备方法
JP7089636B2 (ja) アンジオテンシンｉｉ２型受容体拮抗薬の塩形、結晶形及びその製造方法
AU2019388805B2 (en) Solid form, crystalline form, and crystal form A of FXR agonist, and preparation method therefor and application thereof
CN110869382B (zh) 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途
WO2024136884A1 (en) Salts including crystalline salts of 25-hydroxy-cholest-5-en-3-sulfate and methods for preparing same
TWI378929B (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
RU2800751C2 (ru) Кристаллическая или аморфная форма агонистов fxr, представляющих собой производные стероидов, способ их получения и их применение
CN107663198A (zh) 奥美沙坦酯及其制备方法和用途
HK40019731A (en) Crystalline or amorphous form of steroid derivative fxr agonist, preparation method therefor and use thereof
HK40019731B (en) Crystalline or amorphous form of steroid derivative fxr agonist, preparation method therefor and use thereof
HK40015161A (en) Crystalline forms of obeticholic acid
Valkonen Structural characteristics and properties of substituted cholanoates and N-substituted cholanamides
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
WO2018209667A1 (zh) 多环杂环化合物的晶型、其制备方法、应用及组合物
HK1254413A1 (en) Polymorphic crystalline forms of obeticholic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003943

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190702

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40003943

Country of ref document: HK